<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Paul S. Aisen</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Southern California</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-3696-418X" target="_blank">0000-0002-3696-418X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Clinical trials, Immunotherapy</td>
</tr>
</table>
Paul S. Aisen
Overview
Paul S. Aisen is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Southern California. Their research focuses on Clinical trials, Immunotherapy, with particular emphasis on Alzheimer's Disease. With an h-index of 180, Aisen is among the most cited researchers in the neuroscience field[@orcid2026].
Aisen's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Clinical trials, Immunotherapy, publishing in high-impact journals including Lancet Neurol.
...<table class="infobox infobox-researcher">
<tr>
<th class="infobox-header" colspan="2">Paul S. Aisen</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Photo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Affiliations</td>
<td>University of Southern California</td>
</tr>
<tr>
<td class="label">Country</td>
<td>USA</td>
</tr>
<tr>
<td class="label">H-index</td>
<td>180</td>
</tr>
<tr>
<td class="label">ORCID</td>
<td><a href="https://orcid.org/0000-0002-3696-418X" target="_blank">0000-0002-3696-418X</a></td>
</tr>
<tr>
<td class="label">Research Focus</td>
<td>[Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Mechanisms</td>
<td>Clinical trials, Immunotherapy</td>
</tr>
</table>
Paul S. Aisen
Overview
Paul S. Aisen is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Southern California. Their research focuses on Clinical trials, Immunotherapy, with particular emphasis on Alzheimer's Disease. With an h-index of 180, Aisen is among the most cited researchers in the neuroscience field[@orcid2026].
Aisen's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Clinical trials, Immunotherapy, publishing in high-impact journals including Lancet Neurol.
Based at University of Southern California, Aisen collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Research Focus
Disease Areas
- [Alzheimer's Disease](/diseases/alzheimers-disease)
Mechanisms of Interest
- Clinical trials
- Immunotherapy
Programmatic Emphasis
Aisen's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease[@long2019]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Methods and Data Strategy
Within the Clinical trials, Immunotherapy domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
Translational Relevance
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Key Publications
[Alzheimer's disease clinical trials](https://doi.org/10.1016/S1474-4422(20)30040-8). Lancet Neurol, 2020.[@alzheimers2020]
Recent Research
Recent PubMed-indexed publications (2024-present):
[Evaluating evidence-based recruitment strategies for Alzheimer's disease and related dementias clinical trial research: A literature review.](https://pubmed.ncbi.nlm.nih.gov/41831376/). The journal of prevention of Alzheimer's disease. 2026.
[Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults.](https://pubmed.ncbi.nlm.nih.gov/41724695/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026.
[Relationship between age and severity of cognitive impairment at diagnosis for early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.](https://pubmed.ncbi.nlm.nih.gov/41614286/). Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026.
[A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41478826/). The journal of prevention of Alzheimer's disease. 2026.
Collaborators and Research Network
[Reisa A. Sperling](/researchers/reisa-sperling), [R. Terry Bartus](/researchers/tomas-bartus), [Jessica B. Langbaum](/researchers/jessica-langbaum)
Institutional Context
Primary institutional links: [University of Southern California](/university-of-southern-california). These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Open Questions and Future Directions
- How can Clinical trials, Immunotherapy signals be standardized across cohorts and sites without losing disease-stage sensitivity?
- Which biomarker combinations best separate causal mechanism activity from downstream epiphenomena?
- What trial designs can most efficiently translate mechanistic findings in Alzheimer's Disease into clinically meaningful interventions?
External Links
- ORCID: [https://orcid.org/0000-0002-3696-418X](https://orcid.org/0000-0002-3696-418X)
- Google Scholar: [Search for Paul S. Aisen](https://scholar.google.com/scholar?q=author%3A%22Paul+S.+Aisen%22)
- PubMed: [Author search for Paul S. Aisen](https://pubmed.ncbi.nlm.nih.gov/?term=Paul+S.+Aisen%5BAuthor%5D)
See Also
- [Researchers and Institutions Index](/researchers)
- [Diseases Index](/diseases)
- [Mechanisms Index](/mechanisms)
References
[Unknown, Alzheimer's disease clinical trials (2020)](https://doi.org/10.1016/S1474-4422(20)
Unknown, ORCID profile for Paul S. Aisen (2026)
[Unknown, Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30617256/)